Medtronic (Medtronic) ROC %

: 7.20% (As of Jan. 2024)

View and export this data going back to 1980. Start your Free Trial

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Medtronic's annualized return on capital (ROC %) for the quarter that ended in Jan. 2024 was 7.20%.

As of today (2024-04-19), Medtronic's WACC % is 6.17%. Medtronic's ROC % is 6.18% (calculated using TTM income statement data). Medtronic generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.

Medtronic ROC % Historical Data

The historical data trend for Medtronic's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Array ( [0] => - [1] => - [2] => - [3] => - [4] => - [5] => 7.99 [6] => 8.33 [7] => 6.06 [8] => 7.22 [9] => 5.49 )

Medtronic Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

ROC %

7.99

8.33

6.06

7.22

5.49

Medtronic Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
ROC %																6.72	7.35	4.78	5.28	7.20

Medtronic ROC % Calculation

Medtronic's annualized Return on Capital (ROC %) for the fiscal year that ended in Apr. 2023 is calculated as:

	ROC % (A: Apr. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Apr. 2022 )	+	Invested Capital (A: Apr. 2023 ))	/ count )
=	5830 * ( 1 - 29.46% )	/	( (73877	+	75906)	/ 2 )
=	4112.482	/	74891.5
=	5.49 %

where

	Invested Capital		(A: Apr. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	90981	-	6531	-	( 10573	-	max(0, 12394	-	23059	+	10573	))
=	73877

	Invested Capital		(A: Apr. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	90948	-	7083	-	( 7959	-	max(0, 9051	-	21675	+	7959	))
=	75906

Medtronic's annualized Return on Capital (ROC %) for the quarter that ended in Jan. 2024 is calculated as:

	ROC % (Q: Jan. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Oct. 2023 )	+	Invested Capital (Q: Jan. 2024 ))	/ count )
=	6012 * ( 1 - 9.17% )	/	( (75792	+	75926)	/ 2 )
=	5460.6996	/	75859
=	7.20 %

where

	Invested Capital		(Q: Oct. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	90087	-	6561	-	( 7734	-	max(0, 9659	-	22081	+	7734	))
=	75792

	Invested Capital		(Q: Jan. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	90836	-	6589	-	( 8321	-	max(0, 9793	-	22513	+	8321	))
=	75926

Note: The Operating Income data used here is four times the quarterly (Jan. 2024) data.

Medtronic (NYSE:MDT) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Medtronic's WACC % is 6.17%. Medtronic's ROC % is 6.18% (calculated using TTM income statement data). Medtronic generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Medtronic ROC % Related Terms

Thank you for viewing the detailed overview of Medtronic's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.

Medtronic (Medtronic) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medtronic PLC (NYSE:MDT) » Definitions » ROC %

Comparable Companies

Traded in Other Exchanges

MDTN:Mexico 1MDT:Italy 2M6:Germany 2M6:Germany 2M6:Germany 2M6:Germany MDTC34:Brazil MDT:Austria MDT:Argentina

Address

Lower Hatch Street, 20 On Hatch, Dublin, IRL, 2

Website

https://www.medtronic.com

One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.

Executives

Brett A. Wall	officer: EVP & Group Pres Restora Thera	710 MEDTRONIC PARKWAY, LC300, MINNEAPOLIS MN 55432
Gregory L Smith	officer: EVP Global Ops & Supply Chain	710 MEDTRONIC PARKWAY, LC300, MINNEAPOLIS MN 55432
Michael Marinaro	officer: EVP & President, Surgical OU	710 MEDTRONIC PARKWAY NE, LC300, MINNEAPOLIS MN 55432
Hoedt Rob Ten	officer: EVP & President EMEAC	710 MEDTRONIC PKWY, MSLC300, MINNEAPOLIS MN 55432
Gregory P Lewis	director	C/O HONEYWELL INTERNATIONAL INC., 300 SOUTH TRYON STREET, CHARLOTTE NC 28202
Sean Salmon	officer: EVP & Group President Diabetes	MEDTRONIC PLC, 710 MEDTRONIC PARKWAY, LC300, MINNEAPOLIS MN 55432
Lidia Fonseca	director	358 SOUTH MAIN STREET, BURLINGTON NC 27215
Karen L Parkhill	officer: EVP & Chief Financial Officer	1717 MAIN STREET, MC 6402, DALLAS TX 75201
Ivan K Fong	officer: EVP GENERAL COUNSEL & SECR	3M CENTER, ST. PAUL MN 55144-1000
Robert John White	officer: EVP & President MITG	MEDTRONIC PLC, 710 MEDTRONIC PKWY MS LC300, MINNEAPOLIS MN 55432
Richard H Anderson	director	MEDTRONIC, INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604
Bradley E Lerman	officer: SVP General Counsel & Corp Sec	MEDTRONIC, INC., 710 MEDTRONIC PKWY MSLC300, MINNEAPOLIS MN 55432
Geoffrey Martha	officer: Sr VP, Strategy & Bus Dev	710 MEDTRONIC PKWAY, MS LC300, MINNEAPOLIS MN 55432
Jennifer M Kirk	officer: Chief Accounting Officer	5 GREENWAY PLAZA, SUITE 110, HOUSTON TX 77046
John R Liddicoat	officer: EVP & President of Americas	MEDTRONIC PLC, 710 MEDTRONIC PKWY, MS LC300, MINNEAPOLIS MN 55432